Inhibition of both c-Met and EGFR signaling shows synergistic antitumor activity in non-small cell lung cancer model

被引：1
|
作者：
Tammam, Jennifer G.
Davis, Lenora
Ware, Chris
Reilly, John F.
Deshmukh, Sujal V.
Dinsmore, Christopher
Marshall, Gary
Harrington, Elizabeth A.
Pan, Bo-Sheng
Lutterbach, Bart A.
Majumder, Pradip K.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-C209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C209
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
    Gao, H-F.
    Wu, Y-L.
    Yang, J-J.
    Zhang, X-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S125 - S125
  • [42] Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer
    Rastogi, Ichwaku
    Rajanna, Supriya
    Webb, Andrew
    Chhabra, Gagan
    Foster, Brad
    Webb, Brian
    Puri, Neelu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 477 (04) : 937 - 944
  • [43] Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
    Yagishita, Shigehiro
    Hamada, Akinobu
    CURRENT DRUG TARGETS, 2014, 15 (14) : 1263 - 1272
  • [44] Analysis of C-MET Amplification Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion
    Xu, C.
    Wang, W.
    Zhuang, W.
    Chen, G.
    Tian, Y.
    Xu, J.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1944 - S1945
  • [45] Strengthening Context-Dependent Anticancer Effects on Non-Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR
    Zhang, Yu-Wen
    Staal, Ben
    Essenburg, Curt
    Lewis, Steven
    Kaufman, Dafna
    Vande Woude, George F.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) : 1429 - 1441
  • [46] Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
    I. Watermann
    B. Schmitt
    F. Stellmacher
    J. Müller
    R. Gaber
    Ch. Kugler
    N. Reinmuth
    R. M. Huber
    M. Thomas
    P. Zabel
    K. F. Rabe
    D. Jonigk
    A. Warth
    E. Vollmer
    M. Reck
    T. Goldmann
    Diagnostic Pathology, 10
  • [47] Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
    Watermann, I.
    Schmitt, B.
    Stellmacher, F.
    Mueller, J.
    Gaber, R.
    Kugler, Ch.
    Reinmuth, N.
    Huber, R. M.
    Thomas, M.
    Zabel, P.
    Rabe, K. F.
    Jonigk, D.
    Warth, A.
    Vollmer, E.
    Reck, M.
    Goldmann, T.
    DIAGNOSTIC PATHOLOGY, 2015, 10
  • [48] Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
    Duan, Jianchun
    Yang, Xiaodan
    Zhao, Jun
    Zhuo, Minglei
    Wang, Zhijie
    An, Tongtong
    Bai, Hua
    Wang, Jie
    ONCOTARGET, 2018, 9 (02) : 2660 - 2667
  • [49] Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
    Wang, K.
    Du, R.
    Roy, S.
    Vokes, N.
    Elamin, Y. Y.
    Hume, C. Bueno
    Skoulidis, F.
    Gay, C.
    Blumenschein, G.
    Fossella, F.
    Tsao, A.
    Lee, J. J.
    Rinsurongkawong, W.
    Rinsurongkawong, V.
    Gibbons, D.
    Vaporciyan, A.
    Zhang, J.
    Heymach, J.
    Altan, M.
    Le, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1016 - S1016
  • [50] The HGF/c-Met pathway activates COX-2 in non-small cell lung cancer
    Siegfried, Jill M.
    Gubish, Christopher T.
    de Oliveira, Pierre E. Queiroz
    Stabile, Laura P.
    CANCER RESEARCH, 2006, 66 (08)
12345